mibe Arzneimittel
Private Company
Funding information not available
Overview
mibe GmbH Arzneimittel is a mid-sized, revenue-generating contract development and manufacturing organization (CDMO) and generic drug producer, wholly owned by Dermapharm AG. With over 700 employees at its state-of-the-art facility, it is a key production asset committed to the German manufacturing base. The company has consistently expanded its capabilities over two decades, now offering a broad range of dosage forms including tablets, liquids, sterile products, hormones, and ointments, supported by extensive in-house analytics and logistics.
Technology Platform
Integrated GMP manufacturing platform for multiple dosage forms (tablets, liquids, sterile products, hormones, ointments) supported by extensive in-house analytical laboratories.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
mibe competes within the crowded European generic manufacturing and CDMO sector against large global players (e.g., Viatris, Teva, STADA) and specialized CDMOs. Its key differentiators are its vertical integration within Dermapharm, its broad in-house technological spectrum, and its strategic location as a centralized logistics hub for the group.